Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Homozygous for F508del or heterozygous for F508del and an RF mutation (as defined in the protocol).~* Participants with ppFEV1 of ≥70 percentage points adjusted for age, sex, height.~* Participants with a screening LCI2.5 result ≥7.5.~* Participants who are able to swallow tablets.~Key Exclusion Criteria:~* Clinically significant cirrhosis with or without portal hypertension.~* Colonization with organisms associated with a more rapid decline in pulmonary status.~* Solid organ or hematological transplantation.~Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: OTHER): Participants with genotype F/F received placebo matched to TEZ/IVA fixed dose combination (FDC) in the morning and placebo matched to IVA in the evening for 8 weeks.
- TEZ/IVA (Type: EXPERIMENTAL): Participants with genotype F/F received TEZ/IVA FDC in the morning and IVA in the evening for 8 weeks. Participants with genotype F/RF received TEZ/IVA FDC and placebo matched to IVA in the morning and IVA in the evening for 8 weeks.
- Ivacaftor (Type: EXPERIMENTAL): Participants with genotype F/RF received placebo matched to TEZ/IVA FDC in the morning and IVA in morning and evening for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).